Amylyx Pharmaceuticals, Inc. AMLX
30.29 USD +0.43 (+1.44%)
At closeNov 13, 2026, 6:11 PM EST
30.00 -0.29 -0.96%
After hours · Nov 13, 6:11 PM ET
28.86 Day range 30.72
10.83 52-week range 41.14
- YTD
- +150.75%
- 1 year
- +143.88%
News
benzinga.com Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $39 Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $38 to $39.
defenseworld.net Amylyx Pharmaceuticals Q3 Earnings Call Highlights Amylyx Pharmaceuticals (NASDAQ: AMLX) plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027…- defenseworld.net Amylyx Pharmaceuticals Q3 Earnings Call Highlights Amylyx Pharmaceuticals (NASDAQ: AMLX) plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027…
seekingalpha.com Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Courtney O'Leary Justin Klee - Co-CEO & Director Camille Bedrosian - Chief Medical…
marketbeat.com Amylyx Pharmaceuticals Q3 Earnings Call Highlights Amylyx Pharmaceuticals NASDAQ: AMLX plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027…- benzinga.com Amylyx Pharma Q3 EPS $(0.38), Inline Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.38) per share which met the analyst consensus estimate. This is a 2.7 percent decrease over losses of $(0.37) per share from the same…
businesswire.com Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results.
businesswire.com Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts.
businesswire.com Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences.
businesswire.com Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026.
benzinga.com Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39 Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
schaeffersresearch.com 11 Stocks Most Likely to See a Short Squeeze Rally Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
benzinga.com Amylyx Pharma To Present Phase 3 Topline Data Highlighting Avexitide’s Efficacy And Safety At ObesityWeek 2026 Annual Meeting Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17,
businesswire.com Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
benzinga.com Amylyx Pharma Q2 2026 Earnings Call Transcript Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For…
defenseworld.net Dyadic International (NASDAQ:DYAI) & Amylyx Pharmaceuticals (NASDAQ:AMLX) Critical Review Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) and Dyadic International (NASDAQ: DYAI - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the…
marketbeat.com Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to…
schaeffersresearch.com 10 Stocks With Massive Short Squeeze Potential Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
seekingalpha.com Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
fool.com Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
fool.com Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
fool.com Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.
defenseworld.net BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
defenseworld.net BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
marketwatch.com 20 stocks likely to lose money even if the bull market continues Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
benzinga.com Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57 Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $55 to $57.
benzinga.com Benzinga Bulls and Bears: Ross, Moderna, Webull Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
benzinga.com Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42 Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $30 to $42.
benzinga.com Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55 Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $40 to $55.- benzinga.com Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52 Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.
benzinga.com Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' Radars Today PFSA, BIDU, AMLX, CAST, KLAR were among the stocks seen trending on Tuesday, Aug. 18, 2026.- benzinga.com HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55 HC Wainwright & Co. analyst Andrew S. Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $34 to $55.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers AIxCrypto Hldgs (NASDAQ:AIXC) stock increased by 132.0% to $1.65 during Tuesday's regular session. The market value of their outstanding shares is at $14.3 million. Amylyx Pharmaceuticals…
benzinga.com Crude Oil Gains 1%; US Pending Home Sales Fall In July US stocks fell in midday trading, with S&P 500 down 0.5% and Dow dropping 0.17%. Health care shares rose 1.6%, while tech stocks fell 2.1%.
benzinga.com Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.
benzinga.com Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level Amylyx Pharmaceuticals posts positive Phase 3 avexitide data for post-bariatric hypoglycemia. The company plans a 2026 FDA application.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion. bioAffinity…
benzinga.com Market-Moving News for August 18th XOS: 140% | Xos shares are trading higher after the company announced that it has been awarded a prototype Other Transaction Agreement by the United States Air Force to develop and deliver a…- benzinga.com Amylyx Pharmaceuticals Says LUCIDITY Phase 3 Trial Met Its Primary Endpoint, Demonstrating 55% Reduction in Level 2 and Level 3 Hypoglycemic Events Vs. Placebo LUCIDITY met FDA-agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003)LUCIDITY met all…
benzinga.com Why Flexsteel Industries Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket Flexsteel Industries Inc (FLXS) reported better-than-expected Q4 results, with shares jumping 9% in pre-market trading. Other gainers include PFSA, EJH, XOS, WETO, SGLY, VOGX, WFF, AMLX, and ENRD.…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out…
benzinga.com Amylyx Pharmaceuticals Stock Soars After the Close: Here's Why Amylyx Pharmaceuticals shares are trading higher Monday after the company scheduled a Phase 3 trial results readout for this week.- benzinga.com Amylyx Pharmaceuticals To Announce Phase 3 LUCIDITY Trial Topline Results For Avexitide In Post-Bariatric Hypoglycemia On August 18 At 8:00 a.m. ET Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18,
benzinga.com Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30 Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $24 to $30.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, RH, Aptiv, Sweetgreen, Nike, and others also decline.
benzinga.com This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all changes. AMLX, OFRM, AGMB, SGP initiated with positive outlook.
benzinga.com Earnings Scheduled For March 3, 2026 
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Earnings Scheduled For August 7, 2025